Combinatory therapy of CD patients with glucocorticoids, immunomodulators, and TNF inhibitors may be associated with an increased risk of non-Hodgkin's lymphoma, lung, skin, and other types of cancers, although no causative relationship of anti-TNF antibodies and carcinogenesis has been proven [90]. The gene discussed is TNF; the disease is cancer.